384 related articles for article (PubMed ID: 17604566)
1. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors.
Hakkarainen T; Särkioja M; Lehenkari P; Miettinen S; Ylikomi T; Suuronen R; Desmond RA; Kanerva A; Hemminki A
Hum Gene Ther; 2007 Jul; 18(7):627-41. PubMed ID: 17604566
[TBL] [Abstract][Full Text] [Related]
2. Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells.
Hammer K; Kazcorowski A; Liu L; Behr M; Schemmer P; Herr I; Nettelbeck DM
Int J Cancer; 2015 Aug; 137(4):978-90. PubMed ID: 25604186
[TBL] [Abstract][Full Text] [Related]
3. Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer.
Ranki T; Särkioja M; Hakkarainen T; von Smitten K; Kanerva A; Hemminki A
Int J Cancer; 2007 Jul; 121(1):165-74. PubMed ID: 17315187
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer.
Sarkioja M; Kanerva A; Salo J; Kangasniemi L; Eriksson M; Raki M; Ranki T; Hakkarainen T; Hemminki A
Cancer; 2006 Oct; 107(7):1578-88. PubMed ID: 16948124
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers.
Hoyos V; Del Bufalo F; Yagyu S; Ando M; Dotti G; Suzuki M; Bouchier-Hayes L; Alemany R; Brenner MK
Mol Ther; 2015 Sep; 23(9):1497-506. PubMed ID: 26084970
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D3-inducible mesenchymal stem cell-based delivery of conditionally replicating adenoviruses effectively targets renal cell carcinoma and inhibits tumor growth.
Hsiao WC; Sung SY; Liao CH; Wu HC; Hsieh CL
Mol Pharm; 2012 May; 9(5):1396-408. PubMed ID: 22480282
[TBL] [Abstract][Full Text] [Related]
7. Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model.
Rincón E; Cejalvo T; Kanojia D; Alfranca A; Rodríguez-Milla MÁ; Gil Hoyos RA; Han Y; Zhang L; Alemany R; Lesniak MS; García-Castro J
Oncotarget; 2017 Jul; 8(28):45415-45431. PubMed ID: 28525366
[TBL] [Abstract][Full Text] [Related]
8. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A
Gene Ther; 2007 Jan; 14(1):58-67. PubMed ID: 16900223
[TBL] [Abstract][Full Text] [Related]
9. Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.
Leoni V; Gatta V; Palladini A; Nicoletti G; Ranieri D; Dall'Ora M; Grosso V; Rossi M; Alviano F; Bonsi L; Nanni P; Lollini PL; Campadelli-Fiume G
Oncotarget; 2015 Oct; 6(33):34774-87. PubMed ID: 26430966
[TBL] [Abstract][Full Text] [Related]
10. PolySia-Specific Retargeting of Oncolytic Viruses Triggers Tumor-Specific Immune Responses and Facilitates Therapy of Disseminated Lung Cancer.
Kloos A; Woller N; Gürlevik E; Ureche CI; Niemann J; Armbrecht N; Martin NT; Geffers R; Manns MP; Gerardy-Schahn R; Kühnel F
Cancer Immunol Res; 2015 Jul; 3(7):751-63. PubMed ID: 25701327
[TBL] [Abstract][Full Text] [Related]
11. Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer.
Stoff-Khalili MA; Rivera AA; Stoff A; Michael Mathis J; Rocconi RP; Matthews QL; Numnum MT; Herrmann I; Dall P; Eckhoff DE; Douglas JT; Siegal GP; Zhu ZB; Curiel DT
Int J Cancer; 2007 Feb; 120(4):935-41. PubMed ID: 17131341
[TBL] [Abstract][Full Text] [Related]
12. Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses.
Guse K; Ranki T; Ala-Opas M; Bono P; Särkioja M; Rajecki M; Kanerva A; Hakkarainen T; Hemminki A
Mol Cancer Ther; 2007 Oct; 6(10):2728-36. PubMed ID: 17938266
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.
Ahmed AU; Tyler MA; Thaci B; Alexiades NG; Han Y; Ulasov IV; Lesniak MS
Mol Pharm; 2011 Oct; 8(5):1559-72. PubMed ID: 21718006
[TBL] [Abstract][Full Text] [Related]
14. Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells.
Koski A; Rajecki M; Guse K; Kanerva A; Ristimäki A; Pesonen S; Escutenaire S; Hemminki A
J Gene Med; 2009 Nov; 11(11):966-77. PubMed ID: 19670332
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.
Takagi-Kimura M; Yamano T; Tamamoto A; Okamura N; Okamura H; Hashimoto-Tamaoki T; Tagawa M; Kasahara N; Kubo S
Cancer Sci; 2013 Nov; 104(11):1433-9. PubMed ID: 23962292
[TBL] [Abstract][Full Text] [Related]
16. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.
Ulasov IV; Zhu ZB; Tyler MA; Han Y; Rivera AA; Khramtsov A; Curiel DT; Lesniak MS
Hum Gene Ther; 2007 Jul; 18(7):589-602. PubMed ID: 17630837
[TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells.
Xin H; Kanehira M; Mizuguchi H; Hayakawa T; Kikuchi T; Nukiwa T; Saijo Y
Stem Cells; 2007 Jul; 25(7):1618-26. PubMed ID: 17412895
[TBL] [Abstract][Full Text] [Related]
18. A novel immunocompetent murine model for replicating oncolytic adenoviral therapy.
Zhang L; Hedjran F; Larson C; Perez GL; Reid T
Cancer Gene Ther; 2015 Jan; 22(1):17-22. PubMed ID: 25525035
[TBL] [Abstract][Full Text] [Related]
19. The utility of a tissue slice model system to determine breast cancer infectivity by oncolytic adenoviruses.
Pennington K; Chu QD; Curiel DT; Li BD; Mathis JM
J Surg Res; 2010 Oct; 163(2):270-5. PubMed ID: 20691986
[TBL] [Abstract][Full Text] [Related]
20. Potent antitumoral effects of targeted promoter-driven oncolytic adenovirus armed with Dm-dNK for breast cancer in vitro and in vivo.
Dong X; Qu W; Ma S; Zhu Z; Zheng C; He A; Karlsson A; Xu K; Zheng X
Cancer Lett; 2013 Jan; 328(1):95-103. PubMed ID: 23000515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]